JPMorgan Upgrades BAX, SYK to Overweight, BSX to Neutral, Downgrades ZMH, ABT to Neutral

JPMorgan's Mike Weinstein revised investment ratings on a number of stocks in the Medical Equipment sector Tuesday morning:

• upgraded Baxter (NYSE: BAX) from Neutral to Overweight, $64 price target maintained;
  
• upgraded Styrker (NYSE: SYK) from Neutral to Overweight, price target reduced from $67 to $61;
  
• upgraded Boston Scientific (NYSE: BSX) from Underweight to Neutral, price target reduced from $8 to $7.50;
  
• downgraded Zimmer Holdings (NYSE: ZMH) from Overweight to Neutral, price target reduced from $70 to $62; and
  
• downgraded Abbott Labs (NYSE: ABT) from Overweight to Neutral, $55 price target maintained.

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
• Jefferies Downgrades Calix (CALX) to Hold
• JPMorgan Upgrades Doximity Inc (DOCS) to Neutral 'Given a More Stabilized Macro Backdrop and Little Downside to Our Valuation'